Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Status:
Terminated
Trial end date:
2020-08-17
Target enrollment:
Participant gender:
Summary
Study Objective:
To test if early preemptive hydroxychloroquine therapy can prevent disease progression in
persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom
severity.
Phase:
Phase 3
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators:
Eastern Health Lawson Health Research Institute McMaster University University of Alberta University of British Columbia University of Manitoba University of Minnesota